Prospects of RNA interference therapy for cancer

S. I. Pai, Y. Y. Lin, B. Macaes, A. Meneshian, Chien-Fu Hung, Tzyy Choou Wu

Research output: Contribution to journalArticle

Abstract

RNA interference (RNAi) is a powerful gene-silencing process that holds great promise in the field of cancer therapy. The discovery of RNAi has generated enthusiasm within the scientific community, not only because it has been used to rapidly identify key molecules involved in many disease processes including cancer, but also because RNAi has the potential to be translated into a technology with major therapeutic applications. Our evolving understanding of the molecular pathways important for carcinogenesis has created opportunities for cancer therapy employing RNAi technology to target the key molecules within these pathways. Many gene products involved in carcinogenesis have already been explored as targets for RNAi intervention, and RNAi targeting of molecules crucial for tumor-host interactions and tumor resistance to chemo- or radiotherapy has also been investigated. In most of these studies, the silencing of critical gene products by RNAi technology has generated significant antiproliferative and/or proapoptotic effects in cell-culture systems or in preclinical animal models. Nevertheless, significant obstacles, such as in vivo delivery, incomplete suppression of target genes, nonspecific immune responses and the so-called off-target effects, need to be overcome before this technology can be successfully translated into the clinical arena. Significant progress has already been made in addressing some of these issues, and it is foreseen that early phase clinical trials will be initiated in the very near future.

Original languageEnglish (US)
Pages (from-to)464-477
Number of pages14
JournalGene Therapy
Volume13
Issue number6
DOIs
StatePublished - Mar 2006

Fingerprint

RNA Interference
Neoplasms
Technology
Gene Silencing
Therapeutics
Carcinogenesis
Genes
Radiotherapy
Animal Models
Cell Culture Techniques
Clinical Trials
Drug Therapy

Keywords

  • Apoptosis
  • Cancer therapy
  • Oncogene
  • RNA interference (RNAi)
  • Short interfering RNA (siRNA)

ASJC Scopus subject areas

  • Genetics

Cite this

Prospects of RNA interference therapy for cancer. / Pai, S. I.; Lin, Y. Y.; Macaes, B.; Meneshian, A.; Hung, Chien-Fu; Wu, Tzyy Choou.

In: Gene Therapy, Vol. 13, No. 6, 03.2006, p. 464-477.

Research output: Contribution to journalArticle

Pai, SI, Lin, YY, Macaes, B, Meneshian, A, Hung, C-F & Wu, TC 2006, 'Prospects of RNA interference therapy for cancer', Gene Therapy, vol. 13, no. 6, pp. 464-477. https://doi.org/10.1038/sj.gt.3302694
Pai, S. I. ; Lin, Y. Y. ; Macaes, B. ; Meneshian, A. ; Hung, Chien-Fu ; Wu, Tzyy Choou. / Prospects of RNA interference therapy for cancer. In: Gene Therapy. 2006 ; Vol. 13, No. 6. pp. 464-477.
@article{c5be3e137d804f7fa41d22527fc57823,
title = "Prospects of RNA interference therapy for cancer",
abstract = "RNA interference (RNAi) is a powerful gene-silencing process that holds great promise in the field of cancer therapy. The discovery of RNAi has generated enthusiasm within the scientific community, not only because it has been used to rapidly identify key molecules involved in many disease processes including cancer, but also because RNAi has the potential to be translated into a technology with major therapeutic applications. Our evolving understanding of the molecular pathways important for carcinogenesis has created opportunities for cancer therapy employing RNAi technology to target the key molecules within these pathways. Many gene products involved in carcinogenesis have already been explored as targets for RNAi intervention, and RNAi targeting of molecules crucial for tumor-host interactions and tumor resistance to chemo- or radiotherapy has also been investigated. In most of these studies, the silencing of critical gene products by RNAi technology has generated significant antiproliferative and/or proapoptotic effects in cell-culture systems or in preclinical animal models. Nevertheless, significant obstacles, such as in vivo delivery, incomplete suppression of target genes, nonspecific immune responses and the so-called off-target effects, need to be overcome before this technology can be successfully translated into the clinical arena. Significant progress has already been made in addressing some of these issues, and it is foreseen that early phase clinical trials will be initiated in the very near future.",
keywords = "Apoptosis, Cancer therapy, Oncogene, RNA interference (RNAi), Short interfering RNA (siRNA)",
author = "Pai, {S. I.} and Lin, {Y. Y.} and B. Macaes and A. Meneshian and Chien-Fu Hung and Wu, {Tzyy Choou}",
year = "2006",
month = "3",
doi = "10.1038/sj.gt.3302694",
language = "English (US)",
volume = "13",
pages = "464--477",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Prospects of RNA interference therapy for cancer

AU - Pai, S. I.

AU - Lin, Y. Y.

AU - Macaes, B.

AU - Meneshian, A.

AU - Hung, Chien-Fu

AU - Wu, Tzyy Choou

PY - 2006/3

Y1 - 2006/3

N2 - RNA interference (RNAi) is a powerful gene-silencing process that holds great promise in the field of cancer therapy. The discovery of RNAi has generated enthusiasm within the scientific community, not only because it has been used to rapidly identify key molecules involved in many disease processes including cancer, but also because RNAi has the potential to be translated into a technology with major therapeutic applications. Our evolving understanding of the molecular pathways important for carcinogenesis has created opportunities for cancer therapy employing RNAi technology to target the key molecules within these pathways. Many gene products involved in carcinogenesis have already been explored as targets for RNAi intervention, and RNAi targeting of molecules crucial for tumor-host interactions and tumor resistance to chemo- or radiotherapy has also been investigated. In most of these studies, the silencing of critical gene products by RNAi technology has generated significant antiproliferative and/or proapoptotic effects in cell-culture systems or in preclinical animal models. Nevertheless, significant obstacles, such as in vivo delivery, incomplete suppression of target genes, nonspecific immune responses and the so-called off-target effects, need to be overcome before this technology can be successfully translated into the clinical arena. Significant progress has already been made in addressing some of these issues, and it is foreseen that early phase clinical trials will be initiated in the very near future.

AB - RNA interference (RNAi) is a powerful gene-silencing process that holds great promise in the field of cancer therapy. The discovery of RNAi has generated enthusiasm within the scientific community, not only because it has been used to rapidly identify key molecules involved in many disease processes including cancer, but also because RNAi has the potential to be translated into a technology with major therapeutic applications. Our evolving understanding of the molecular pathways important for carcinogenesis has created opportunities for cancer therapy employing RNAi technology to target the key molecules within these pathways. Many gene products involved in carcinogenesis have already been explored as targets for RNAi intervention, and RNAi targeting of molecules crucial for tumor-host interactions and tumor resistance to chemo- or radiotherapy has also been investigated. In most of these studies, the silencing of critical gene products by RNAi technology has generated significant antiproliferative and/or proapoptotic effects in cell-culture systems or in preclinical animal models. Nevertheless, significant obstacles, such as in vivo delivery, incomplete suppression of target genes, nonspecific immune responses and the so-called off-target effects, need to be overcome before this technology can be successfully translated into the clinical arena. Significant progress has already been made in addressing some of these issues, and it is foreseen that early phase clinical trials will be initiated in the very near future.

KW - Apoptosis

KW - Cancer therapy

KW - Oncogene

KW - RNA interference (RNAi)

KW - Short interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=33645167401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645167401&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302694

DO - 10.1038/sj.gt.3302694

M3 - Article

C2 - 16341059

AN - SCOPUS:33645167401

VL - 13

SP - 464

EP - 477

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -